News from cannabics pharmaceuticals inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 17, 2021, 09:25 ET Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with ...

Feb 16, 2021, 12:49 ET Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the...

Feb 03, 2021, 09:20 ET Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that...

Dec 21, 2020, 09:27 ET Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and...

Nov 16, 2020, 09:25 ET Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and...

Nov 09, 2020, 09:25 ET Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and...

Oct 27, 2020, 09:00 ET Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and...

Oct 21, 2020, 09:00 ET Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and...

Aug 20, 2020, 09:00 ET Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Aug 05, 2020, 09:00 ET Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Jul 14, 2020, 09:20 ET Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Jun 16, 2020, 09:20 ET Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Jun 10, 2020, 09:40 ET Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

May 26, 2020, 09:00 ET Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

May 06, 2020, 09:00 ET Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Apr 27, 2020, 09:30 ET Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Apr 13, 2020, 09:30 ET Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Mar 25, 2020, 09:20 ET Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...
Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research

Mar 18, 2020, 08:40 ET Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...
Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

Mar 11, 2020, 08:40 ET Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Mar 02, 2020, 08:40 ET Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, released an...

Feb 25, 2020, 08:37 ET Cannabics Pharmaceuticals Partners With NewCanna to Commence Research Based on Colombian Indigenous Cannabis Landraces

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Feb 18, 2020, 08:22 ET Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Feb 11, 2020, 08:35 ET Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...

Jan 27, 2020, 08:25 ET Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit Anti-Tumor Properties on Gastrointestinal Cancer Cells

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today...